{
    "data": [
        {
            "id": "4660486",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-31T02:49:47-05:00",
                "isLockedPro": false,
                "commentCount": 33,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1311247307/image_1311247307.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107268",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "512190",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4660486-bristol-myers-squibbs-winning-formula-dividends-m-and-a-and-innovation"
            }
        },
        {
            "id": "4659173",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-23T12:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 46,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1272401412/image_1272401412.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Too Many Headwinds To Ignore, Despite The Stellar Management",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "510834",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4659173-bristol-myers-squibb-many-headwinds-to-ignore-despite-stellar-management"
            }
        },
        {
            "id": "4659361",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-23T04:24:25-05:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1689585487/image_1689585487.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Aggressive M&A, A Riskier Strategy To Fix The Growth Challenge",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "511179",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4659361-bristol-myers-squibb-aggressive-m-and-a-riskier-strategy-to-fix-the-growth-challenge"
            }
        },
        {
            "id": "4658434",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-19T15:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 93,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/684126754/image_684126754.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: This Dividend Contender Is A Steal Right Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "509763",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4658434-bristol-myers-squibb-this-dividend-contender-is-a-steal-right-now"
            }
        },
        {
            "id": "4657459",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-12T10:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 53,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1689585487/image_1689585487.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: A Nice Deal For This Bargain Pharma Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "508757",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4657459-bristol-myers-squibb-nice-deal-bargain-pharma-stock"
            }
        },
        {
            "id": "4654400",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-28T07:10:00-05:00",
                "isLockedPro": false,
                "commentCount": 46,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1016186674/image_1016186674.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Is A Great Buy, But These 5+% Yielding Bargains Are Better",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "504965",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4654400-bristol-myers-squibb-great-buy-these-5-plus-percent-yielding-bargains-better"
            }
        },
        {
            "id": "4653853",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-23T02:57:15-05:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1424217301/image_1424217301.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: The Patent Expiry Challenge",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107221",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "503811",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4653853-bristol-myers-squibb-the-patent-expiry-challenge"
            }
        },
        {
            "id": "4653620",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-22T13:00:01-05:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1409300273/image_1409300273.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: A Bitter Pill But Still A Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "503955",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4653620-bristol-myers-squibb-stock-"
            }
        },
        {
            "id": "4653456",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-21T13:32:10-05:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1689585487/image_1689585487.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: A Tough But Cheap Spot",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "503742",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4653456-bristol-myers-squibb-a-tough-but-cheap-spot"
            }
        },
        {
            "id": "4652616",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-17T04:46:33-05:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1689585487/image_1689585487.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Bright Future Ahead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105586",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "502495",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4652616-bristol-myers-squibb-stock-mirati-acquistion-bright-future-ahead"
            }
        },
        {
            "id": "4642453",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-22T08:53:38-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1477214805/image_1477214805.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Acquisition Of Mirati Makes Sense",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "495303",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4642453-bristol-myers-squibb-acquisition-mirati-makes-sense"
            }
        },
        {
            "id": "4642375",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-21T10:24:08-04:00",
                "isLockedPro": false,
                "commentCount": 79,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288877316/image_1288877316.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Time To Get Greedy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104980",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "494938",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4642375-bristol-myers-squibb-time-to-get-greedy"
            }
        },
        {
            "id": "4639735",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-09T12:00:33-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/672159879/image_672159879.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "492117",
                            "type": "sentiment"
                        },
                        {
                            "id": "492118",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4639735-bristol-myers-mirati-takeover-pharma-buying-crown-jewels-or-dud"
            }
        },
        {
            "id": "4637542",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-28T14:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/104018545/image_104018545.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: How Cheap Is Cheap Enough?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "488690",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4637542-bristol-myers-squibb-how-cheap-is-cheap-enough"
            }
        },
        {
            "id": "4637862",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-28T14:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1617236488/image_1617236488.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers: Out Of Favor (Rating Upgrade)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "489349",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4637862-bristol-myers-out-of-favor"
            }
        },
        {
            "id": "4637617",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-27T06:09:16-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077050386/image_1077050386.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Looks Grossly Overvalued With LOE Taking A Bite Out Of Topline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106601",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "489059",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4637617-bristol-myers-squibb-looks-grossly-overvalued-loe-dragging-topline"
            }
        },
        {
            "id": "4637363",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-26T05:56:43-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1617235960/image_1617235960.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Undervalued Already, But Could Go Lower",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "488611",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4637363-bristol-myers-squibb-stock-undervalued-already-but-could-go-lower-maintain-buy"
            }
        },
        {
            "id": "4637329",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-26T03:33:13-04:00",
                "isLockedPro": false,
                "commentCount": 55,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1617235960/image_1617235960.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Close To Fair Value, Headwinds For Next Few Years",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102518",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "488594",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4637329-bristol-myers-squibb-close-to-fair-value-headwinds-for-next-few-years"
            }
        },
        {
            "id": "4635527",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-15T21:36:08-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1399981576/image_1399981576.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Pharma And Government Playing 'Chicken' Over New Drug Pricing Rules",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "486194",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4635527-bristol-myers-squibb-pharma-and-government-playing-chicken-over-new-drug-pricing-rules"
            }
        },
        {
            "id": "4630773",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-24T08:30:19-04:00",
                "isLockedPro": false,
                "commentCount": 50,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1313800795/image_1313800795.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Buyers Are Loading Up After Its Recent Shares Plunge",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "480733",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4630773-bristol-myers-squibb-buyers-loading-up-after-recent-stock-plunge"
            }
        },
        {
            "id": "4630729",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-24T02:20:26-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Top Defensive Pick During Recessions With A Value Proposition",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56142",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "480607",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4630729-bristol-myers-squibb-top-defensive-pick-during-recessions-with-a-value-proposition"
            }
        },
        {
            "id": "4630707",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-23T23:33:48-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1423987752/image_1423987752.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Patents, Profits, And Prognosis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "480660",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4630707-bristol-myers-squibb-patents-profits-and-prognosis"
            }
        },
        {
            "id": "4621469",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-29T08:03:02-04:00",
                "isLockedPro": false,
                "commentCount": 56,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1311247307/image_1311247307.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb's Bright Future Unfolds Beyond Q2 2023 Turmoil",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "474239",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4621469-bristol-myers-squibb-bright-future-beyond-q2-2023-turmoil"
            }
        },
        {
            "id": "4619047",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-23T07:56:36-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962527/image_1386962527.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Is A Buy At Current Support (Technical Analysis)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106871",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "472550",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4619047-bristol-myers-squibb-is-a-buy-at-current-support-technical-analysis"
            }
        },
        {
            "id": "4619010",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-23T01:07:37-04:00",
                "isLockedPro": false,
                "commentCount": 97,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1283384596/image_1283384596.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: The Gift Has Arrived",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "472554",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4619010-bristol-myers-squibb-gift-arrived"
            }
        },
        {
            "id": "4618761",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-21T11:08:50-04:00",
                "isLockedPro": false,
                "commentCount": 69,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1400621080/image_1400621080.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Bristol-Myers Squibb Phenomenon: A Game Changer In The Pharmaceutical Industry",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "472377",
                            "type": "sentiment"
                        },
                        {
                            "id": "472378",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4618761-the-bristol-myers-squibb-phenomenon-a-game-changer-in-pharmaceutical-industry"
            }
        },
        {
            "id": "4617894",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-19T07:20:00-04:00",
                "isLockedPro": false,
                "commentCount": 92,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288877316/image_1288877316.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers: Potentially Set To Soar And Too Cheap To Ignore",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "471532",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4617894-bristol-myers-potentially-set-to-soar-and-too-cheap-to-ignore"
            }
        },
        {
            "id": "4615747",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-07T11:50:25-04:00",
                "isLockedPro": false,
                "commentCount": 63,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324628/image_1418324628.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb Is A Buy At Current Valuation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80836",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "468870",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4615747-bristol-myers-squibb-buy-at-current-valuation"
            }
        },
        {
            "id": "4615745",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-07T11:38:57-04:00",
                "isLockedPro": false,
                "commentCount": 60,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324628/image_1418324628.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Battling Exclusivity Headwinds",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "468812",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4615745-bristol-myers-squibb-battling-exclusivity-headwinds"
            }
        },
        {
            "id": "4615567",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-07T07:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324628/image_1418324628.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Attractive Buying Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "468680",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4615567-bristol-myers-squibb-attractive-buying-opportunity"
            }
        },
        {
            "id": "4615550",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-06T14:24:01-04:00",
                "isLockedPro": false,
                "commentCount": 62,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1370660000/image_1370660000.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Back In The Doldrums - Or Just Pausing For Breath?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "468667",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4615550-bristol-myers-squibb-in-the-doldrums-or-pausing-for-breath"
            }
        },
        {
            "id": "4609469",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-05T12:24:41-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/583804546/image_583804546.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Weakness Offers Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "461199",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4609469-bristol-myers-squibb-weakness-offers-opportunity"
            }
        },
        {
            "id": "4609362",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-05T08:05:00-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/843765220/image_843765220.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Take The Red Pill",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "461168",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4609362-bristol-myers-squibb-take-the-red-pill"
            }
        },
        {
            "id": "4608184",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-30T09:56:58-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1442179368/image_1442179368.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "High Quality Dividend Growth Near 52-Week Lows: Bristol-Myers Squibb Is A Good Bet",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106014",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "459673",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4608184-bristol-myers-squibb-is-a-good-bet-near-52-week-lows"
            }
        },
        {
            "id": "4600383",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-05T05:52:37-04:00",
                "isLockedPro": false,
                "commentCount": 52,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324628/image_1418324628.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Attractive Entry As New Products Sales Accelerate",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106413",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "454063",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4600383-bmy-attractive-entry-as-new-products-sales-accelerate"
            }
        },
        {
            "id": "4597713",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-28T09:00:27-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1290675747/image_1290675747.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Q1 Earnings: Is CEO Caforio's Sudden Departure A Concern?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "452770",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4597713-bristol-myers-squibb-q1-earnings-ceo-caforio-sudden-departure-concern"
            }
        },
        {
            "id": "4594807",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-18T17:00:41-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1394663007/image_1394663007.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: A Recession-Resistant Route Forward",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53262",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "450695",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4594807-bristol-myers-squibb-recession-resistant-route-forward"
            }
        },
        {
            "id": "4593154",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-10T08:26:10-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365749374/image_1365749374.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "GSK Vs. Bristol-Myers Squibb: Who's More Underrated By Mr. Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "448856",
                            "type": "sentiment"
                        },
                        {
                            "id": "448857",
                            "type": "sentiment"
                        },
                        {
                            "id": "448858",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4593154-gsk-vs-bristol-myers-squibb-more-underrated-by-market"
            }
        },
        {
            "id": "4590397",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-27T13:48:09-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325876463/image_1325876463.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Nobody Panic! Share Price Stumble Shouldn't Last",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "446518",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4590397-bristol-myers-squibb-nobody-panic-share-price-stumble-shouldnt-last"
            }
        },
        {
            "id": "4590261",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-27T04:37:34-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/156276777/image_156276777.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Unraveling The Complexities Of Valuation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105667",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "446292",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4590261-bristol-myers-squibb-unraveling-the-complexities-of-valuation"
            }
        },
        {
            "id": "4590146",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-26T04:50:04-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324628/image_1418324628.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Growth Story And Valuation Is Convincing",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "446178",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4590146-bristol-myers-squibb-stock-growth-story-and-valuation-is-convincing"
            }
        },
        {
            "id": "4580258",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-21T12:32:20-05:00",
                "isLockedPro": false,
                "commentCount": 47,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324628/image_1418324628.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers: Looking Good For 2023",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "439284",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4580258-bristol-myers-looking-good-2023"
            }
        },
        {
            "id": "4579951",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-20T05:43:47-05:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1362921092/image_1362921092.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What To Expect From Bristol-Myers Squibb In 2023",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "438939",
                            "type": "sentiment"
                        },
                        {
                            "id": "438940",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4579951-bristol-myers-squibb-stock-what-to-expect-in-2023"
            }
        },
        {
            "id": "4570759",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-18T20:26:59-05:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324628/image_1418324628.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb's New Products Need More Insurance Coverage, But Still A Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "432136",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4570759-bristol-myers-squibb-new-products-need-more-insurance-coverage-still-buy"
            }
        },
        {
            "id": "4570499",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-18T02:04:45-05:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324628/image_1418324628.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Bristol Myers Squibb Is The Better Buy From U.S. Large Cap Pharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105817",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "431857",
                            "type": "sentiment"
                        },
                        {
                            "id": "431858",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4570499-why-bristol-myers-squibb-is-the-better-buy-from-us-large-cap-pharma"
            }
        },
        {
            "id": "4568507",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-08T08:10:00-05:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1248262649/image_1248262649.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Cash Rich And Trades Under 10x PE",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "430069",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4568507-bristol-myers-squibb-cash-rich-and-trades-under-10x-pe"
            }
        }
    ]
}